Welcome to our dedicated page for Adaptive Biotechnologies SEC filings (Ticker: ADPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Adaptive Biotechnologies Corporation filings document financial results, governance matters, registered common stock, and material events for a commercial-stage biotechnology issuer. Recent 8-K reports furnish quarterly and annual operating results, press releases, investor presentation materials, and disclosures tied to the company’s MRD business and immune medicine platform.
The company’s proxy materials cover board and shareholder voting matters, executive compensation, equity awards, and related governance disclosures. Other filings identify ADPT common stock listed on Nasdaq and disclose material agreement activity connected to research and development collaborations, including immune medicine and TCR-antigen programs.
Adaptive Biotechnologies Corp Chief Financial Officer Kyle Piskel executed a small mandated share sale tied to equity compensation taxes. On May 18, 2026, he sold 3,115 shares of common stock at $13.04 per share to cover tax withholding obligations from vesting restricted stock units. The company’s equity incentive plan required this “sell to cover” transaction, and the footnote states it was not a discretionary trade. After the sale, Piskel directly held 256,725 shares of Adaptive Biotechnologies common stock.
Morgan Stanley Smith Barney LLC filed a Form 144 notice reporting a proposed sale of 3,160 Restricted Stock Units with an effective date of 05/15/2026. The filing also shows an earlier sale by Kyle Piskel of 18,672 shares on 03/11/2026 for $245,863.56.
Adaptive Biotechnologies Corp: Amendment No. 4 to a Schedule 13G/A reports ownership details from Viking Global entities and removes David C. Ott as a reporting person after his retirement effective March 31, 2026.
Viking Global Investors (VGI) is reported to beneficially own 29,993,708 shares of Common Stock, equal to 18.8% of the class as of March 31, 2026. Related entities include Viking Global Performance LLC (22,002,189 shares, 13.8%), Viking Global Equities Master Ltd. (21,562,143 shares, 13.5%), Viking Long Fund Master Ltd. (7,991,519 shares, 5.0%), and Viking Global Equities II (440,046 shares, 0.3%). O. Andreas Halvorsen and Rose S. Shabet are each reported as beneficial owners of 29,993,708 shares (18.8%).
Adaptive Biotechnologies reported higher revenue and a smaller loss for the quarter ended March 31, 2026. Total revenue rose to $70.9 million from $52.4 million, driven by Minimal Residual Disease (MRD) revenue of $67.1 million, including $9.0 million of regulatory milestone revenue.
Immune Medicine revenue declined to $3.8 million following termination of the Genentech collaboration. Net loss attributable to the company narrowed to $20.0 million, or $0.13 per share, from $29.9 million. Adjusted EBITDA improved to a loss of $2.5 million from $12.7 million. Cash, cash equivalents and marketable securities totaled $237.2 million.
Adaptive Biotechnologies reported strong first quarter 2026 results driven by its Minimal Residual Disease (MRD) business. Revenue was $70.9 million, up 35% from the prior-year quarter, with MRD revenue of $67.1 million, a 53% increase. Immune Medicine revenue was $3.8 million, down 57%, reflecting lower Genentech-related activity.
Net loss improved to $20.0 million from $29.8 million, and Adjusted EBITDA loss narrowed to $2.5 million from $12.7 million. The company ended March 31, 2026 with $237.2 million in cash, cash equivalents and marketable securities and raised full-year 2026 MRD revenue guidance to $260–$270 million, implying 22–27% annual growth.
Adaptive Biotechnologies Corp President and COO Julie Rubinstein reported an option exercise and related share sale. On April 27, 2026, she completed an open-market sale of 19,037 shares of common stock at a weighted average price of $14.23 per share.
That same day, she exercised stock options to acquire 14,707 shares of common stock at an exercise price of $8.46 per share from a grant vesting over four years and expiring in 2033. The filing states these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan.
Adaptive Biotechnologies Corp President and COO Julie Rubinstein reported a mix of option exercises and share sales. Over April 22–24, 2026, she exercised stock options covering 44,166 shares of Common Stock at an exercise price of $8.46 per share and sold 57,180 shares in open-market transactions at weighted average prices around $14 per share, as detailed in price ranges in the footnotes. After these transactions, she directly holds 382,132 shares of Common Stock and 60,438 stock options. The filing notes that all transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 18, 2025.
Adaptive Biotechnologies Corporation is asking shareholders at its virtual 2026 annual meeting on June 5, 2026 to elect two Class I directors, approve 2025 executive pay on an advisory basis, and ratify Ernst & Young LLP as auditor for 2026.
The proxy highlights 2025 revenue of $277.0 million versus $179.0 million in 2024, driven by minimal residual disease revenue of $212.3 million and 105,587 clonoSEQ tests. Net cash used in operations fell to $46.0 million from $95.2 million, and cash, cash equivalents and marketable securities were $227.2 million as of December 31, 2025.
Adaptive Biotechnologies President and COO Julie Rubinstein reported a series of pre-planned stock transactions in common stock. Under a Rule 10b5-1 trading plan, she exercised stock options to acquire a total of 56,047 shares at exercise prices of $8.46 and $12.14 per share, then sold 69,061 shares in open‑market transactions at weighted average prices in the mid‑$14 range. Following these exercises and sales, she continues to hold a substantial direct ownership position in Adaptive Biotechnologies common stock.